EXELIXIS, INC. - 8-K Filing
Federal Circuit affirms validity of Exelixis' three U.S. patents; generic competitor's FDA approval delayed until January 2030. (Items: 8.01 Other Events)
Tickers: $EXEL
Federal Circuit affirms validity of Exelixis' three U.S. patents; generic competitor's FDA approval delayed until January 2030. (Items: 8.01 Other Events)
Tickers: $EXEL